RxDoctor Payments Data

Edgar Salas, MD

Gastroenterology · Danville, KYNPI 1265666770

Payments from drug & device makers

$6,189in general payments, 2019–2025

Across 287 payments — averaging $21.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Boston Scientific$698
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$687
  • Phathom Pharmaceuticals, Inc.$449
  • Takeda Pharmaceuticals U.S.A., Inc.$420
  • Sanofi$215
  • plus $2K from 23 others

What the payments were for

  • Travel & lodging$2284%
  • Food & beverage$5,96196%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,189 in reported general payments places this provider in the 60th percentile of 207 gastroenterology providers in Kentucky.

See all gastroenterology providers in Kentucky

Medicare billing

Part B allowed, 2024
$152,406
Medicare patients
421
Services billed
1,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase49$193,438
XifaxanRifaximin33$102,770
LinzessLinaclotide52$35,305
Ursodiol12$3,427
Dexlansoprazole DrDexlansoprazole11$1,776
Pantoprazole Sodium119$1,232
Colestipol Hcl20$956
Lansoprazole11$403
Famotidine24$320
Dicyclomine Hcl16$304
Baclofen19$258
Spironolactone22$253
Lactulose20$213
Omeprazole23$185
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen24$130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$2,172$228,743101 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$687$102,77033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 207 gastroenterology providers in Kentucky.

Other gastroenterology in Danville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →